Analyze Your Search

Hints:

  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Fatty Liver Disease
  Follow Topic   Edit Search
Your search returned 63 results
from the time period: last 90 days.
Sort by Relevance / Date Group By Journal / No Grouping
Medicine
DescriptorName: Humans. DescriptorName: Non-alcoholic Fatty Liver Disease... AbstractText: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver condition worldwide. However, its etiology and fundamental pathophysiology for the disease process are poorly understood. In this study, we thus used bioinformatics to identify candidate genes potentially causative of severe NAFLD AbstractText: Gene expression profile data GSE49541 were downloaded from ...
Infectious Diseases (1)
Fatty Liver (2), Alcoholic Fatty Liver (1), Steatohepatitis (1), more mentions
Medicine
DescriptorName: Non-alcoholic Fatty Liver Disease... conditions and medications taken by diabetic patients with NAFLD and identifying characteristics that may impact liver disease severity or clinical management.Adults with type 2 diabetes have a high prevalence of nonalcoholic fatty liver disease (NAFLD) and increased risk of developing advanced liver disease.
Endocrine Disorders (2), Neuroscience (1), Cardiovascular Diseases (1)
Liver Diseases (6), Diabetes Mellitus, Type 2 (2), Fibrosis (1), more mentions
Medicine
Abstract: Several prediction models for fatty liver disease (FLD) are available with limited externally validation and less comprehensive evaluation. The aim was to perform external validation and direct comparison of 4 prediction models (the Fatty Liver Index, the Hepatic Steatosis Index, the ZJU index, and the Framingham Steatosis Index) for FLD both in the overall population and the obese subpopulation ...
Anti-Obesity and Weight Loss (5)
Fatty Liver (4), Obesity (1), more mentions
The American journal of cardiology
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a risk factor for coronary artery disease... Based on this classification, all patients were divided into 4 subgroups as grade 0 (no fatty liver disease), grade 1, grade 2, and grade 3. Hierarchical logistic regression and Cox proportional regression analysis were used to establish the relation between NAFLD grade and outcomes.
Fatty Liver (3), Myocardial Infarction (2), Coronary Artery Disease (1), more mentions
Gastroenterology 
AbstractText: Cardiovascular disease (CVD) is the leading cause of death among patients with non-alcoholic fatty liver disease (NAFLD. Moderate drinking (vs abstinence) is associated with lower risk of CVD in the general population. We assessed whether alcohol use is associated with CVD risk in patients with NAFLD AbstractText: We analyzed data from participants in the Coronary Artery Risk Development ...
Cardiovascular Diseases (4), Endocrine Disorders (2), Anti-Obesity and Weight Loss (1)
Cardiovascular Diseases (2), Diabetes Mellitus (2), Fatty Liver (1), more mentions
Annals of surgery 
... to compare the influence of sleeve gastrectomy (SG) versus Roux-en-Y gastric bypass (RYGB) on liver function in bariatric patients with non-alcoholic fatty liver disease (NAFLD) in a randomized clinical trial (NCT01806506) AbstractText: Rapid weight loss and malabsorption after bariatric surgery in patients with NAFLD or steatohepatitis (NASH) may ...
Anti-Obesity and Weight Loss (4), Blood Disorders and Hematology (1), Infectious Diseases (1)
Dyslipidemias (1), Fatty Liver (1), Alcoholic Fatty Liver (1), more mentions
Diabetes care
AbstractText: To compare the efficacy of ipragliflozin versus pioglitazone in patients with type 2 diabetes complicated by nonalcoholic fatty liver disease (NAFLD) AbstractText: In this open-label, randomized, active-controlled trial, we randomly assigned 66 patients with type 2 diabetes and NAFLD to receive ipragliflozin 50 mg (n = 32) or ...
Endocrine Disorders (4)
Diabetes Mellitus, Type 2 (4), Fatty Liver (2), more mentions
European journal of cancer (Oxford, England : 1990)
BACKGROUND: Management of metabolic complications of long-term adjuvant endocrine therapy in early breast cancer remained an unmet need. We aimed to compare the effects of tamoxifen (TMX) and aromatase inhibitors (AIs) on the risk of fatty liver in conjunction with longitudinal changes in the serum lipid parameters. METHODS: Among 1203 subjects who were taking adjuvant TMX or AI (anastrozole or letrozole) without fatty liver at baseline, those taking TMX or AI were 1:1 matched on the propensity score. The primary outcome was newly developed fatty liver detected on annual liver ultrasonography. RESULTS: Among 328 matched subjects (mean age 53.5 years, body mass index 22.9 kg/m(2)), 62 cases of fatty liver in the TMX group and 41 cases in the AI group were detected in a total of 987.4 person-years. The incidence rate of fatty liver was higher in the TMX group than in the AI group (128.7 versus 81.1 per 1000 person-years, P = 0.021), particularly within the first 2 years of therapy. TMX was associated with an increased 5-year risk of newly developed fatty liver (adjusted hazard ratio 1.61, P = 0.030) compared with AI independent of obesity and cholesterol level. Subjects who developed fatty liver had higher triglycerides (TGs) and lower high-density lipoprotein cholesterol (HDL-C) level at baseline than those without, which was sustained during follow-up despite the serum cholesterol-lowering effect of TMX. CONCLUSIONS: TMX independently increased the 5-year risk of newly developed fatty liver compared with AI in postmenopausal women with early breast cancer. Our findings suggest the need for considering the risk of fatty liver as a different adverse event profile between AI and TMX, particularly in patients with obesity, high TGs and low HDL-C.
Anti-Obesity and Weight Loss (3), Oncology (3)
Fatty Liver (11), Breast Neoplasms (4), Obesity (2), more mentions
Alimentary pharmacology & therapeutics
Letter: Helicobacter pylori in lean and obese patients with non-alcoholic fatty liver disease..
Anti-Obesity and Weight Loss (2)
Alcoholic Fatty Liver (2), more mentions
Alimentary pharmacology & therapeutics
Letter: non-alcoholic fatty liver disease and polycystic ovary syndrome-evidence for low vitamin D status contributing to the link..
Polycystic Ovary Syndrome (2), Alcoholic Fatty Liver (2), more mentions
Hepatology (Baltimore, Md.)
Comments on increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis..
Fibrosis (2), Fatty Liver (2), more mentions
Hepatology (Baltimore, Md.)
Re-discussion on linearity between fibrosis stages and mortality risk in non-alcoholic fatty liver disease patients..
Fibrosis (2), Alcoholic Fatty Liver (2), more mentions
Alimentary pharmacology & therapeutics
Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers-authors' reply..
Fatty Liver (2), more mentions
Alimentary pharmacology & therapeutics
Letter: Mendelian randomisation to investigate moderate alcohol consumption in nonalcoholic fatty liver disease; modest effects need large numbers..
Fatty Liver (2), more mentions
Alimentary pharmacology & therapeutics
Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity..
Anti-Obesity and Weight Loss (2)
Obesity (2), Alcoholic Fatty Liver (2), more mentions
Alimentary pharmacology & therapeutics
Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity-authors' reply..
Anti-Obesity and Weight Loss (2)
Obesity (2), Alcoholic Fatty Liver (2), more mentions
Digestive diseases and sciences
Does Metabolic Syndrome and Not the Inflammatory Load Predict Nonalcoholic Fatty Liver Disease Severity in Inflammatory Bowel Disease Patients?.
Fatty Liver (2), Inflammatory Bowel Diseases (2), more mentions
American family physician
Nonalcoholic Fatty Liver Disease: Identifying Patients at Risk of Inflammation or Fibrosis..
Fibrosis (2), Fatty Liver (2), more mentions
AIDS (London, England)
Fatty liver disease in HIV: common, underappreciated, and understudied..
Fatty Liver (2), more mentions
Gastroenterology
How to approach a patient with non-alcoholic fatty liver disease..
Alcoholic Fatty Liver (2), more mentions
1 2 3 4  | Next Page»